88IV - <300233.CN> - Shandong Jincheng Pharmaceutical and Chemical Co.,Ltd.

Share This

Create Your Own Business Intelligence Website
Input the stock code or the company name		Search

Basic Datum
Company name	资产收益	每股收益	每股资产	收入增长	利润增长
JINCHENG PHARM	0.14%	0.01	7.93	-19.83%	-94.91%

Company name	价位	五日表现	五日换手	十日表现	十日换手
JINCHENG PHARM	19.8	5.46%	18.29%	-0.02%	36.64%

所属板块：创业板医药山东生物医药

Related links
www.jinchengpharm.com

Related news
金城醫藥(300233.SZ)：目前公司谷胱甘肽、腺甘蛋氨酸...
格隆匯5月17日亅金城醫藥(300233)(300233.SZ)在投資者互動平台表示，公司依托於在化學及生物合成領域深耕多年的經驗，構建起「化學+生物合成」的雙合成研產平台，公司重點面向生物催化和生物合成兩大方向，聚焦手性藥物及中間體的酶催化和高附加值的生物合成產品。目前公司谷胱甘肽、腺甘蛋氨酸、PQQ以及4AA、煙鹼等產品均已實現產業化生產及銷售，對公司發展形成有力支撐
金城醫藥(300233.SZ)：未開展TMA的研究
格隆匯5月17日亅金城醫藥(300233)(300233.SZ)在投資者互動平台表示，目前公司未開展TMA的研究，技術方面從合成路徑上看可以采用酶催化工藝進行生產。（責任編輯：周文凱）
金城醫藥(300233.SZ)：頭孢羥氨苄干混懸劑增加規格取...
格隆匯5月16日亅金城醫藥(300233)(300233.SZ)公布，山東金城醫藥集團股份有限公司之全資子公司上海金城素智藥業有限公司(以下簡稱「金城素智」)收到國家藥品監督管理局下發的頭孢羥氨苄干混懸劑《藥品補充申請批准通知書》(證書編號：2024B012112、2024B012111、2024B012110)
金城醫藥(300233.SZ)：氯諾昔康收到化學原料藥上市申...
格隆匯5月14日亅金城醫藥(300233)(300233.SZ)公布，全資子公司北京金城泰爾制藥有限公司收到國家藥品監督管理局下發的化學原料藥上市申請批准通知書，化學原料藥名稱：氯諾昔康。氯諾昔康一種非甾體抗炎藥，具有較強的鎮痛和解熱作用。（責任編輯：王治強 HF013）
≫More

Comment

Top Gain / Loss	Show All Charts

Value
Name	Updated	Value	Change	Change %
JINCHENG PHARM	05-13 15:00	19.8	▼ 0.27	▼ 1.35%
≫More

More Topics：
\| Real Est HK Construction Real Est China Rentals \| REITs Agri Enviro \| fertilizer producers Water \| Util HK Banks \| China Banks \| Insure \| China Finance \| Brokers Consumer \| Food \| Supermarket Diary Education merchant \| Garment \| HK Apparel \| Sports Appl \| Auto \| jewel \| Beauty \| HK retail Shipping \| Shipbuilding \| Harbour \| Highways \| Airlines \| logistics \| Expo \| Textile Paper \| Resource \| Rare Earths \| Steel \| Gold mine \| Mach Petro \| Electricity \| Nuclear power \| New Energy \| gas \| coal Infra \| Railway \| Build Mat \| Cement China IT \| Communication Gambling China Lottery media film Drugs		HK Housing Market \| Real Estate Market \| \| \| \| \| \| HK Stock \| Stock Trend \| capital flow \| A Shares \| ETF \| IPO \| \| Gold \| Gold Jew \| Oil \| Commodity \| G20 \| Top 500 USD \| GBD \| EURO \| Swiss franc \| AUD \| NZD \| CAD \| YEN \| RMB \| Korean Won \| Taiwan Dollar (TWD) iBond \| Emerging markets Lang \| Andy Xie \| Simon Ting \| Law Ka-Chung \| LiuDongliang \| XieXuren \| FanGang \| Mobius \| BillGross \| Roubini \| Faber Financial and political policy \| Central Bank Monetary Policy \| Social Security Fund \| \| \| \|

Mobile | Full

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map

Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved

Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.